Mitchell H. Finer, Ph.D.

Dr. Mitchell (Mitch) H. Finer is an Entrepreneur at MPM and BioImpact Capital, an affiliate manager of MPM. He is the President of Research and Development at portfolio company ElevateBio and CEO of its subsidiary Life Edit Therapeutics. Mitch has been instrumental in founding, building and leading a number of portfolio companies. He is the founder and former CEO of Oncorus (NASDAQ: ONCR) and CODA Biotherapeutics. Mitch serves on several portfolio company boards, including CODA, ElevateBio, and Oncorus.

Prior to joining MPM and BioImpact Capital, Mitch was the CSO of bluebird bio. For three decades, he has focused on drug development utilizing the novel platforms of cell and gene therapy, cancer immunotherapy and regenerative medicine, and he has held several senior leadership roles in companies developing these therapies. Mitch has also served as CEO of Intracel Corporation and Genteric, Vice President Research for Cell Genesys and the Gencell division of Aventis Pharma (now Sanofi) and Senior Vice President of Development at Novacell (now Viacyte). He also successfully co-founded a retinal disease gene therapy company Avalanche Biotechnologies (now Adverum Biotechnologies) where he serves as a member of the board of directors.

Mitch has been named inventor on 15 issued U.S. patents in the field of engineered proteins, cells and viruses in the fields of gene therapy of orphan disease, regenerative medicine and immune oncology. He received his Ph.D. in Biochemistry and Molecular Biology from Harvard University and a B.S. in Biochemistry and Microbiology from the University of California at Berkeley. He completed a post-doctoral fellowship at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology.